scholarly journals The change in platelet count in patients with acute coronary syndrome 6 months after coronary stent implantation

2015 ◽  
Vol 26 (6) ◽  
pp. 661-664
Author(s):  
Zhanqiang Zhang ◽  
Lihong An ◽  
Dayong Du ◽  
Xiaohui Lai ◽  
Fang Wang ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Platelet Count ◽  
Stent Implantation ◽  
Coronary Stent ◽  
Coronary Syndrome ◽  
Coronary Stent Implantation

Aggressive Antiplatelet Therapy Before Coronary Stent Implantation in Acute Coronary Syndrome with Essential Thrombocythemia

Angiology ◽  
2003 ◽  
Vol 54 (4) ◽  
pp. 485-490 ◽  
Author(s):  
Mitsunori Fujimura ◽  
Masashi Akaike ◽  
Midori Kato ◽  
Nobuyuki Takamori ◽  
Masahiro Abe ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Antiplatelet Therapy ◽  
Essential Thrombocythemia ◽  
Stent Implantation ◽  
Coronary Stent ◽  
Coronary Syndrome ◽  
Coronary Stent Implantation

Coronary stent implantation, eosinophils and the Kounis hypersensitivity associated acute coronary syndrome

2011 ◽  
Vol 217 (1) ◽  
pp. 67-69 ◽  
Author(s):  
Nicholas G. Kounis ◽  
Grigorios Tsigkas ◽  
George Almpanis ◽  
George N. Kounis ◽  
Andreas Mazarakis ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Stent Implantation ◽  
Coronary Stent ◽  
Coronary Syndrome ◽  
Coronary Stent Implantation

Insights into stent implantation for coronary artery lesions caused by Kawasaki disease

2020 ◽  
Vol 30 (7) ◽  
pp. 911-918
Author(s):  
Etsuko Tsuda
Keyword(s):  
Acute Coronary Syndrome ◽  
Coronary Artery ◽  
Kawasaki Disease ◽  
Adverse Effects ◽  
Stent Implantation ◽  
Long Term Results ◽  
Coronary Artery Lesions ◽  
Coronary Syndrome ◽  
Coronary Stent Implantation

AbstractFifty years have passed since the first report of Kawasaki disease in 1967, and the prevalence of acute coronary syndrome in Kawasaki disease patients with coronary artery lesions exceeding 40 years old has increased. Primary coronary stent implantation is currently an acceptable method in ischaemic coronary heart disease in adults. However, it is unknown whether the stent implantation is effective or not in this population. As the clue to answer this question, I reviewed the references on Kawasaki disease patients who underwent the stent implantations between 1997 and 2019. Thirty-three patients underwent stent implantations for 34 coronary arteries. Adverse effects in the late period were found in 19 (68%) of 28 vessels with follow-up angiograms. There were complete occlusion 9, restenosis 8, and migration 2. A new aneurysm formation was found in 7 (37%) among the 19 vessels, and 6 (86%) of the 7 vessels were drug-eluting stent and 5 were found after the procedure for chronic total occlusion. The adverse effects free-rate at 1 year and 3 years were 57 and 25%, respectively. At present, the usefulness of stent implantation in the long-term results was scarce. Even if primary percutaneous coronary intervention without a stent implantation is performed for acute coronary syndrome, it can be expected to maintain the patency of the culprit lesion for several years. It is better to avoid a stent implantation as long as possible in this population. Knowing the long-term efficacy and complications of stent implantations is important for deciding the procedure.

Use of PRECISE-DAPT Score and Admission Platelet Count to Predict Mortality Risk in Patients With Acute Coronary Syndrome

Angiology ◽  
2019 ◽  
Vol 70 (9) ◽  
pp. 867-877 ◽  
Author(s):  
Nuccia Morici ◽  
Giovanni A. Tavecchia ◽  
Laura Antolini ◽  
Maria R. Caporale ◽  
Silvia Cantoni ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Platelet Count ◽  
Antiplatelet Therapy ◽  
Mortality Risk ◽  
Stent Implantation ◽  
Dual Antiplatelet Therapy ◽  
Predictive Accuracy ◽  
Bleeding Complications ◽  
Coronary Syndrome ◽  
Coronary Events

The PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Antiplatelet Therapy (PRECISE-DAPT) score has been validated to predict bleeding complications in patients undergoing stent implantation and dual antiplatelet therapy. This score does not include the platelet count (PC), which has been shown to be an independent marker of mortality in patients with acute coronary syndrome (ACS). We assessed the role of the PRECISE-DAPT score calculated on admission for mortality risk prediction and evaluated whether the predictive accuracy of this score improved by adding the PC. In a retrospective cohort study of 1000 patients with ACS, after adjustment for relevant covariates, a PRECISE-DAPT score ≥25 was independently associated with mortality (hazard ratio [HR]: 7.91; 95% confidence interval [CI]: 4.37-14.30). When this score was combined with PC, compared to patients with PRECISE-DAPT <25 and PC ≥150 × 109/L, the adjusted HR was 7.2 (95% CI 2.4-21.6) for those with PRECISE-DAPT <25 and PC <150 × 109/L; 10.7 (95% CI: 5.2-21.9) for those with PRECISE-DAPT ≥25 and PC ≥150 × 109/L; and 17.9 (95% CI 7.0-45.4) for those with PRECISE-DAPT ≥25 and PC <150 × 109/L. Selecting thresholds for high-risk designation, the PRECISE-DAPT score integrated with PC had a higher prediction value, compared to the PRECISE-DAPT and Global Registry of Acute Coronary Events scores.

scholarly journals Mobilization of progenitor cells and vessel healing after implantation of SYNERGY in acute coronary syndrome

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Masashi Sakuma ◽  
Setsu Nishino ◽  
Takahisa Nasuno ◽  
Michiya Kageyama ◽  
Michiaki Tokura ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Acute Coronary Syndrome ◽  
Progenitor Cells ◽  
Stent Implantation ◽  
Healing Process ◽  
Coronary Syndrome ◽  
Neointimal Thickness ◽  
Coronary Stent Implantation ◽  
Coronary Angioscopy ◽  
Neointimal Coverage

AbstractThis study was aimed to compare the vascular healing process of a SYNERGY stent with that of a PROMUS PREMIER stent in patients with acute coronary syndrome (ACS). In 71 patients with ACS, undergoing coronary stent implantation using the SYNERGY stent (n = 52) or PROMUS PREMIER stent (n = 19), we measured circulating CD34+/CD133+/CD45null cells and CD34+/KDR+ cells and observed vascular healing at the stented sites using optical coherence tomography (OCT) and coronary angioscopy. On the day 7, circulating CD34+/CD133+/CD45null cells increased in SYNERGY group (P < 0.0001), while it did not change in PROMUS group. The CD34+/KDR+ cells also increased in SYNERGY group (P < 0.0001) but less significantly in the PROMUS group (P < 0.05). The OCT-based neointimal thickness (P < 0.0005) and neointimal coverage rate (P < 0.05) at 12 months were greater in SYNERGY group, compared with PROMUS group. The coronary angioscopy-based neointimal coverage grade at 12 months was also greater in SYNERGY group (P < 0.001). In overall patients, the change in CD34+/KDR+ cells on the day 7 correlated with the OCT-based neointimal thickness at 12 months (R = 0.288, P < 0.05). SYNERGY stent seems to have potential advantages over PROMUS PREMIER stent for ACS patients in terms of vascular healing process at the stented sites.

scholarly journals Prospective external validation of PRECISE-DAPT score for prediction of bleeding and thrombosis after coronary stent implantation

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
A Jaspattananon ◽  
N Wongpraparut ◽  
S Naowapanich ◽  
S Satsue ◽  
S Seesung
Keyword(s):  
Stent Implantation ◽  
External Validation ◽  
Coronary Stent ◽  
P Value ◽  
Final Decision ◽  
Funding Source ◽  
Bleeding Events ◽  
Thrombotic Risk ◽  
Coronary Syndrome ◽  
Coronary Stent Implantation

Abstract Background Optimal duration of dual antiplatelet therapy (DAPT) after coronary stent implantation depends on bleeding and thrombotic risk in an individual patient. The PRECISE-DAPT score is recommended for adjusting of optimal DAPT duration. Purpose To assess external validation of PRECISE-DAPT score for prediction of out-of-hospital bleeding and thrombosis after coronary stent implantation in prospective manner. Methods We prospectively enrolled patients who underwent coronary stent implantation and received DAPT in our institution during June 2018 through December 2019. Out-of-hospital bleeding and thrombotic events were assessed for validation of PRECISE-DAPT score. Results Six hundred and two patients were enrolled. The mean age was 65.0±11.7 years and 28.2% were female. STEMI, NSTEMI/UA and chronic coronary syndrome were 24.4%, 22.6%, 53% respectively. Prevalence of prior bleeding was 6.3%. Mean follow-up period was 312±72 days. Bleeding events were 5.1%. High PRECISE-DAPT score (score ≥25) had significantly higher bleeding events (9.4% vs 2.4%, P-value &lt;0.001), which were divided into major TIMI bleeding (3.4% vs 0.3%, P-valve 0.003) and minor TIMI bleeding (6.0% vs 2.2%, P-valve 0.014). MACE (CV death, MI, stroke) were 7% and significantly higher in high PRECISE-DAPT score (10.7% vs 4.6%, P-valve 0.004), compared with low PRECISE-DAPT score. Conclusions In real-world prospective study, high PRECISE DAPT score (score ≥25) is associated with high bleeding and thrombotic events. Because of increased both events in high PRECEISE-DAPT score, shortening DAPT duration requires physician final decision-making to balance future bleeding and thrombosis. Funding Acknowledgement Type of funding source: Public hospital(s). Main funding source(s): Siriraj grants for medical research and education, Faculty of Medicine Siriraj Hospital, Mahidol University

Abstract 16088: Comparison of Aspirin and Clopidogrel Therapy With Clopidogrel Alone Use Following Coronary Stent Implantation in Patients With Acute Myocardial Infarction

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Jin Sup Park ◽  
Kwang Soo Cha ◽  
Donghun Shin ◽  
Dae Sung Lee ◽  
Hye Won Lee ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Stent Implantation ◽  
Coronary Stent ◽  
Coronary Stenting ◽  
Observational Result ◽  
Coronary Syndrome ◽  
Coronary Stent Implantation ◽  
Increased Risk ◽  
One Year

Introduction: Dual antiplatelet (DAP) therapy with aspirin and a thienopyridine following coronary stenting is superior to aspirin alone use in reducing cardiovascular events in both acute coronary syndrome and stable angina. However, there is a doubt whether DAP therapy is more effective and safer than clopidogrel alone use in secondary prevention. Hypothesis: We assessed the hypothesis that we compared retrospectively clopidogrel alone use with DAP therapy in acute myocardial infarction (MI) patients treated with coronary stent. Methods: From the Korean MI registry, we selected a total of 13,348 patients who underwent coronary stent implantation and were discharged on clopidogrel alone use (n = 85, 0.6%) and DAP therapy (n = 13,263, 99.4%). Propensity score matching was used and two cohorts of 1:5 nearest neighbor matched patients were obtained to eliminate biased estimates. The primary endpoint was the composite of major adverse cardiac events (MACE; all-cause death, MI, or revascularization) at one-year. Results: In the two matched cohorts of clopidogrel alone use (n = 85) and DAP therapy (n = 425), there was no difference in all-cause death (3.1 vs. 3.5%, p = 0.82), cardiovascular death (2.1 vs. 2.4%, p = 0.892), MI (1.6 vs. 1.2%, p = 0.75), revascularization (6.6 vs. 8.2%, p = 0.583), and the composite of cumulative MACE (11.3 vs. 12.9%, p = 0.665) at median follow-up period of 11.8 months. Compared to DAP therapy, clopidogrel alone use was not associated with increased risk of all-cause death (hazard ratio [HR] 1.11, 95% confidence interval [CI] 0.314-3.93, p = 0.871), MI (HR 0.38, 95% CI 0.17-11.2, p = 0.763), revascularization (HR 0.808, 95% CI 0.353-1.851, p = 0.615), and the composite of MACE (HR 1.129, 95% CI 0.585-2.178, p = 0.717) at one-year. Conclusions: This observational study showed that clopidogrel alone use following coronary stenting was not associated with increased mortality and worse clinical outcomes at one-year compared to DAP therapy in patients with acute MI. Further studies are needed to support this observational result.

Sign in / Sign up

Export Citation Format

Share Document